Roquefort Therapeutics (LON:ROQ) Shares Down 10.5% – What’s Next?

Roquefort Therapeutics plc (LON:ROQ) shares were down 10.5% during trading on Wednesday . The stock traded as low as GBX 2.32 ($0.03) and last traded at GBX 2.33 ($0.03). Approximately 1,770,633 shares were traded during trading, a decline of 13% from the average daily volume of 2,032,882 shares. The stock had previously closed at GBX 2.60 ($0.03).

Roquefort Therapeutics Trading Down 2.0 %

The company has a debt-to-equity ratio of 12.37, a current ratio of 0.79 and a quick ratio of 3.07. The business’s 50-day moving average is GBX 3.84 and its two-hundred day moving average is GBX 3.93. The firm has a market cap of £2.97 million, a P/E ratio of -230.20 and a beta of 0.05.

Insider Transactions at Roquefort Therapeutics

In related news, insider Stephen Paul West acquired 400,000 shares of the company’s stock in a transaction dated Tuesday, February 4th. The shares were bought at an average price of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($14,942.10). Company insiders own 60.40% of the company’s stock.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.